The Children's Oncology Group (COG) Statistics and Data Center (SDC), collaborates with the COG membership to design, conduct analyze and report the results of clinical trials of the treatment of childhood cancers and associated, laboratory-based, companion studies of the biology of these malignancies. Specifically, COG SDC personnel: Participate in the setting and evaluation of COG research priorities; collaborate in the development of study concepts and protocols. In particular, members of the SDC develop the study's statistical considerations; collaborate in the development and implementation of the study's case- report forms for the Group's clinical data management system; monitor study enrollment and the quality and completeness of study data submission; produce interim reports on study conduct and adverse event experience for the Group membership and protocol-specified interim analyses of study outcomes for the Group's Data and Safety Monitoring Committees; produce final reports of the study results for the Group membership; collaborate with laboratories to link specimen data and high dimensional genomics data with COG clinical and outcome data and to produce analyses of these data for publication; produce Technical Reports, detailing analyses performed for Group abstracts and manuscripts; conduct database and methodological research of relevance to the Group's research; perform CDUS and results reporting; monitor the performance of COG member institutions, producing reports for the Group's Institutional Performance monitoring Committee; provide data derived from COG studies to investigators external to the SDC in accordance with the policies and procedures of the Group; participate in National Clinical Trials Network initiatives and CTEP committees as appropriate.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180899-02
Application #
8838750
Study Section
Special Emphasis Panel (ZCA1-GRB-I (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-04-15
Project End
2019-02-28
Budget Start
2015-03-01
Budget End
2016-02-29
Support Year
2
Fiscal Year
2015
Total Cost
$6,709,202
Indirect Cost
$516,419
Name
University of Florida
Department
Biostatistics & Other Math Sci
Type
Schools of Medicine
DUNS #
969663814
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Erbe, Amy K; Wang, Wei; Carmichael, Lakeesha et al. (2018) Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clin Cancer Res 24:189-196
Hwang, Eugene I; Kool, Marcel; Burger, Peter C et al. (2018) Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. J Clin Oncol :JCO2017764720
Yanik, Gregory A; Parisi, Marguerite T; Naranjo, Arlene et al. (2018) Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. J Nucl Med 59:502-508
Marks, Lianna J; Pei, Qinglin; Bush, Rizvan et al. (2018) Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 65:e27375
Malempati, Suman; Weigel, Brenda J; Chi, Yueh-Yun et al. (2018) The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer :
Hawkins, Douglas S; Chi, Yueh-Yun; Anderson, James R et al. (2018) Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. J Clin Oncol 36:2770-2777
Cajaiba, Mariana M; Dyer, Lisa M; Geller, James I et al. (2018) The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing. Cancer 124:3381-3389
Roberts, Kathryn G; Reshmi, Shalini C; Harvey, Richard C et al. (2018) Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. Blood 132:815-824
McCarten, Kathleen M; Metzger, Monika L; Drachtman, Richard A et al. (2018) Significance of pleural effusion at diagnosis in pediatric Hodgkin lymphoma: a report from Children's Oncology Group protocol AHOD0031. Pediatr Radiol 48:1736-1744
Rajbhandari, Presha; Lopez, Gonzalo; Capdevila, Claudia et al. (2018) Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma. Cancer Discov 8:582-599

Showing the most recent 10 out of 317 publications